Modis Therapeutics, a biopharmaceutical company focused on developing disease-modifying therapies for rare genetic diseases with high unmet medical need, announced yesterday that it has named Matthew R Patterson as its Director.

Patterson is the co-founder and Chief Executive Officer of Audentes Therapeutics. He has more than 25 years of experience in the research, development, and commercialization of novel treatments for rare diseases and has held positions of senior management in both private and public biotechnology companies. Previously, he worked for Genzyme Corporation, BioMarin Pharmaceutical, and Amicus Therapeutics.

Prior to Audentes Patterson was an Entrepreneur-In-Residence with OrbiMed. He also presently serves as Chairman of the Alliance for Regenerative Medicine and is a member of the Board of Directors for Homology Medicines.

Joshua Grass, Chief Executive Officer of Modis Therapeutics, said, 'We are pleased to welcome Matt to the Modis Board of Directors. We believe that his operational expertise and extensive management experience complement the current Board and that his knowledge of rare disease drug development and his success leading Audentes through tremendous growth will be invaluable to Modis as the company grows.'